Cargando…
Cost-consequence model comparing eltrombopag and romiplostim in pediatric patients with chronic immune thrombocytopenia
BACKGROUND: Immune thrombocytopenia (ITP) is an auto-immune disorder characterized by enhanced platelet destruction and, subsequently, the potential for increased bleeding. Thrombopoietin receptor (TPO-R) agonists have recently emerged as promising therapies for ITP patients who are refractory to ot...
Autores principales: | Tremblay, Gabriel, Dolph, Mike, Bhor, Menaka, Said, Qayyim, Roy, Anuja, Elliott, Brian, Briggs, Andrew |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223346/ https://www.ncbi.nlm.nih.gov/pubmed/30464564 http://dx.doi.org/10.2147/CEOR.S177338 |
Ejemplares similares
-
Cost-consequence model comparing eltrombopag versus romiplostim for adult patients with chronic immune thrombocytopenia
por: Tremblay, Gabriel, et al.
Publicado: (2018) -
Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment
por: Bidika, Erjola, et al.
Publicado: (2020) -
Cost-minimization analysis comparing eltrombopag vs romiplostim for adults with chronic immune thrombocytopenia
por: Patwardhan, Pallavi, et al.
Publicado: (2021) -
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
por: Tremblay, Gabriel, et al.
Publicado: (2019) -
Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia
por: Al-Samkari, Hanny, et al.
Publicado: (2023)